U030 “Bread n’ Butter with a Side of Nutella”: Short n’ Sweet, High-Yield Updates on Management of Bread n’ Butter Dermatologic Diseases
DESCRIPTION
This session will focus on reviewing the newest evidence-based treatment(s) for common dermatologic diseases including treatment of warts, psoriasis, skin cancer, cosmetic dermatology, and dermatopathology. Practicing dermatologist often do not have time to keep up with the latest evidence in clinical management. This session includes five high-impact, high-yield, “short n’ sweet” updates in management of diseases that dermatologists most commonly encounter.
LEARNING OBJECTIVES
Summarize database and comparative effectiveness research on existing treatment(s) for common dermatologic diseases and specific disease phenotypes.
Summarize updates in new, existing and down-the-pipeline treatments for common dermatologic diseases.
Diagnose and determine treatment of common diseases using the newest technology in dermatopathology.
SCHEDULE
7:30 AM
High-Yield Overview of the Changing Landscape of Management of Autoinflammatory Diseases
Erin Barrett, MD, FAAD
7:40 AM
High-Yield Updates in Treatment of Skin Cancer
Vanessa Voss, MD, FAAD
7:50 AM
Cosmetic Kernels
Ronald Sulewski, MD, FAAD
8:00 AM
Clinico-Dermato-Pathologic Correlation: Practical Tips and Updates
Corey J. Georgesen, MD, FAAD
8:10 AM
High-Yield Pearls for Management of Warts with Therapeutic Updates
Jennifer Adams, MD, FAAD
8:20 AM
High-Yield Treatment Pearls and Updates for Psoriasis
Sarah Lonowski, MD, MBA, FAAD
DIRECTOR
Erin Barrett, MD, FAAD
SPEAKERS
Jennifer Adams, MD, FAAD
Corey J. Georgesen, MD, FAAD
Sarah Lonowski, MD, MBA, FAAD
Ronald Sulewski, MD, FAAD
Vanessa Voss, MD, FAAD
DISCLOSURES
Jennifer Adams, MD, FAAD
L'Oreal – Advisory Board(Honoraria);
Erin Barrett, MD, FAAD
Eli Lilly – Investigator(No Compensation Received); Guidepoint Global, LLC – Other(Fees); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(No Compensation Received); Sanofi Speaker Programs – Speaker/Faculty Education(Honoraria);
Corey J. Georgesen, MD, FAAD
No financial relationships exist with ineligible companies.
Sarah Lonowski, MD, MBA, FAAD
AstraZeneca – Investigator(Grants/Research Funding); Bristol Myers Squibb – Other(Other Financial Benefit); Eli Lilly – Investigator(Grants/Research Funding); Priovant Therapeutics – Advisory Board(No Compensation Received); Veradermics – Consultant (1099 relationship)(Fees);
Ronald Sulewski, MD, FAAD
No financial relationships exist with ineligible companies.
Vanessa Voss, MD, FAAD
Castle Biosciences – Advisory Board(Honoraria), Investigator(Grants/Research Funding);